Investor centre

Investor Centre.
Results, reports and disclosures.

Quarterly results, investor presentations, annual reports and statutory disclosures of Morepen Laboratories Limited.

Selected publication

Q1 FY27: commercial execution and record quarterly results

04 AUG 2026 · Revenue of INR 5,753 million and EBITDA of INR 877 million reported for Q1 FY27.

Open official document

The source document opens in a new tab. The official investor archive remains below.

Q1 FY27 performance

Recent performance.
At a glance.

Open Q1 FY27 presentation

5,753 INR million

Revenue

Highest-ever quarterly revenue

877 INR million

EBITDA

Highest-ever quarterly EBITDA - 3x YoY

8,250 INR million

CDMO mandate

Entered commercial supplies

15.25%

EBITDA margin

Blended EBITDA improves

+111%

Export growth

Prioritisation of customer mix

19%

Medical Devices growth

Maintains strong growth

Investor library

Everything else.
Compact and structured.

Important contacts

Investor & shareholder
contact directory.

Registrar & Share Transfer Agent

MAS Services Limited
T-34, 2nd Floor, Okhla Industrial Area,
Phase-II, New Delhi-110020
011-26387281/82/83
investor@masserv.com

Nodal Officer for IEPF matters

Chief Financial Officer

Ajay Kumar Sharma
2nd Floor, Tower C, DLF Cyber Park,
Udyog Vihar
Sector -20, Gurugram, Haryana - 122016
0124-4892000
investors@morepen.com

Stay close to the published record.

Recent presentations and annual reports lead the experience; all other investor information remains clearly organised behind them.

Talk to our team

Investor Centre.Results, reports and disclosures.